Quoin director buys 6,146 ADSs plus warrants
Following the $4.88 ADS purchase, insider Culverwell added immediately exercisable $6.10-per-ADS warrants and increased his direct holdings to 40,364 ADSs.
Rhea-AI Filing Summary
Quoin Pharmaceuticals, Ltd. (QNRX) director Anthony James Culverwell reported buying both ADSs and warrants linked to the company. On 2026-08-31 he purchased 6,146 ADSs at $4.88 per ADS in a private placement that included 50% ordinary warrant coverage, and also acquired 3,073 ordinary warrants with an exercise price of $6.10 per ADS. Each ADS represents 35 ordinary shares. The warrants are exercisable immediately, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Culverwell directly held 40,364 ADSs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 9,219 shares
Net Buy
2 txns
Insider
Culverwell Anthony James
Role
Director
Bought
9,219 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Ordinary Warrants (Right to Buy) F2, F3, F4, F1 | 3,073 | -- | -- |
| Purchase | ADSs F1, F2 | 6,146 | $4.88 | $30K |
Holdings After Transaction:
Ordinary Warrants (Right to Buy) — 3,073 contracts (Direct);
ADSs — 40,364 shares (Direct)
Footnotes (4)
- F1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2. Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
- F3. The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- F4. The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.
Key Figures
ADSs purchased: 6,146 ADSs
Purchase price per ADS with warrant: $4.88
Warrants purchased: 3,073 ordinary warrants
+4 more
7 metrics
ADSs purchased
6,146 ADSs
Non-derivative purchase on 2026-08-31
Purchase price per ADS with warrant
$4.88
Combined purchase price in private placement
Warrants purchased
3,073 ordinary warrants
Derivative purchase on 2026-08-31 with 50% coverage
Warrant exercise price
$6.10 per ADS
Exercise price of ordinary warrants acquired
ADS holdings after transaction
40,364 ADSs
Direct ownership following 6,146 ADS purchase
ADS to ordinary share ratio
35 ordinary shares per ADS
Representation of Quoin ordinary shares by ADSs
Net shares bought
9,219 shares (ADSs and underlying of warrants)
Total buy-side share count across transactions
Key Terms
American Depositary Shares, ADSs, ordinary warrants, beneficial ownership cap, +1 more
5 terms
ADSs financial
"Ordinary Shares are represented by American Depositary Shares ("ADSs")."
ordinary warrants financial
"The ADSs and accompanying ordinary warrants ("Warrants") were issued"
A warrant that gives its holder the right to buy ordinary shares (common stock) at a fixed price for a set period. Think of it as a coupon that lets an investor purchase a share later at a predetermined price; if the market price rises above that price the coupon is valuable, otherwise it may expire worthless. Investors care because exercising warrants can amplify gains but also dilute existing shareholders by increasing the number of shares outstanding.
beneficial ownership cap financial
"The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap."
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
combined purchase price financial
"were issued at a combined purchase price of $4.88."
FAQ
What did Quoin Pharmaceuticals (QNRX) director Anthony James Culverwell buy in this Form 4?
He purchased 6,146 ADSs and 3,073 ordinary warrants of Quoin Pharmaceuticals on 2026-08-31 in a private placement that included 50% warrant coverage.
At what price were the QNRX ADSs purchased in this Form 4?
The ADSs were purchased at a combined price of $4.88 per ADS with accompanying warrant in Quoin Pharmaceuticals’ private placement.
What is the exercise price of the warrants reported in the QNRX Form 4?
The ordinary warrants reported have an exercise price of $6.10 per ADS and are exercisable immediately, subject to a beneficial ownership cap.
How many QNRX ADSs does Anthony James Culverwell hold after these transactions?
After the reported purchase, Anthony James Culverwell directly holds 40,364 ADSs of Quoin Pharmaceuticals.
When do the Quoin Pharmaceuticals warrants reported in this Form 4 expire?
The warrants expire on the earlier of five years from the issuance date or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome.
AI-generated analysis. How Rhea-AI works. Not financial advice.
